WO1998048846A1 - Light imaging contrast agents - Google Patents
Light imaging contrast agents Download PDFInfo
- Publication number
- WO1998048846A1 WO1998048846A1 PCT/GB1998/001248 GB9801248W WO9848846A1 WO 1998048846 A1 WO1998048846 A1 WO 1998048846A1 GB 9801248 W GB9801248 W GB 9801248W WO 9848846 A1 WO9848846 A1 WO 9848846A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particles
- image
- light
- particulate
- agent
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 91
- 238000003384 imaging method Methods 0.000 title claims abstract description 75
- 239000000463 material Substances 0.000 claims abstract description 18
- 238000001727 in vivo Methods 0.000 claims abstract description 17
- 238000000399 optical microscopy Methods 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims description 190
- 238000000034 method Methods 0.000 claims description 85
- 239000002502 liposome Substances 0.000 claims description 75
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 229920000642 polymer Polymers 0.000 claims description 33
- 230000017531 blood circulation Effects 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 238000000386 microscopy Methods 0.000 claims description 17
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 12
- 238000012014 optical coherence tomography Methods 0.000 claims description 12
- 239000011236 particulate material Substances 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 8
- 239000000975 dye Substances 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 210000005166 vasculature Anatomy 0.000 claims description 8
- 239000000693 micelle Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000002123 temporal effect Effects 0.000 claims description 5
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- 230000000242 pagocytic effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 description 62
- 210000001519 tissue Anatomy 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 239000000243 solution Substances 0.000 description 35
- 239000007789 gas Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- 239000006249 magnetic particle Substances 0.000 description 19
- 239000000839 emulsion Substances 0.000 description 18
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 17
- 239000002105 nanoparticle Substances 0.000 description 16
- 230000003287 optical effect Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 15
- 238000011160 research Methods 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000000149 argon plasma sintering Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 12
- 229960004657 indocyanine green Drugs 0.000 description 12
- 230000005298 paramagnetic effect Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 150000003904 phospholipids Chemical class 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- -1 hydroxy aluminium Chemical compound 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 238000002428 photodynamic therapy Methods 0.000 description 8
- 150000004032 porphyrins Chemical class 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 229940039231 contrast media Drugs 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 7
- 229960004359 iodixanol Drugs 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 6
- 108091006905 Human Serum Albumin Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 238000004624 confocal microscopy Methods 0.000 description 6
- 230000005291 magnetic effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000005294 ferromagnetic effect Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 229920002359 Tetronic® Polymers 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 229940028435 intralipid Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000003801 milling Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002616 MRI contrast agent Substances 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 239000002961 echo contrast media Substances 0.000 description 3
- 210000003191 femoral vein Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000004706 metal oxides Chemical group 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000002907 paramagnetic material Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000003348 petrochemical agent Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910000859 α-Fe Inorganic materials 0.000 description 3
- OYVFJKVYVDYPFV-UHFFFAOYSA-M 3-ethyl-2-[7-(3-ethyl-1,3-benzothiazol-3-ium-2-yl)hepta-2,4,6-trienylidene]-1,3-benzothiazole;iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CC)=C1/C=C/C=C/C=C/C=C1/N(CC)C2=CC=CC=C2S1 OYVFJKVYVDYPFV-UHFFFAOYSA-M 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000005274 electronic transitions Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- KOUAQOCYMAENKN-UHFFFAOYSA-N ethyl 2-bromohexanoate Chemical compound CCCCC(Br)C(=O)OCC KOUAQOCYMAENKN-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000005293 ferrimagnetic effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical compound [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 210000003692 ilium Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000010954 inorganic particle Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005305 interferometry Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052747 lanthanoid Inorganic materials 0.000 description 2
- 150000002602 lanthanoids Chemical class 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000004533 oil dispersion Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011257 shell material Substances 0.000 description 2
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 2
- 229950004777 sodium calcium edetate Drugs 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- ONBWNNUYXGJKKD-UHFFFAOYSA-N 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonic acid;sodium Chemical compound [Na].CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC ONBWNNUYXGJKKD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZMZGFLUUZLELNE-UHFFFAOYSA-N 2,3,5-triiodobenzoic acid Chemical class OC(=O)C1=CC(I)=CC(I)=C1I ZMZGFLUUZLELNE-UHFFFAOYSA-N 0.000 description 1
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical class N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- GGOPTDHVLCAOSV-UHFFFAOYSA-N 3-(diacetylamino)-2,4,6-triiodobenzoic acid Chemical compound CC(=O)N(C(C)=O)C1=C(I)C=C(I)C(C(O)=O)=C1I GGOPTDHVLCAOSV-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 108010056388 Albunex Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1c(*)c(N)c(*)cc1C(OCCOC(*(*)c(cc1O)ccc1C(C1=CC=C(*)C[C@]1O1)=C(C=C2)C1=CC2=O)=N)=O Chemical compound Cc1c(*)c(N)c(*)cc1C(OCCOC(*(*)c(cc1O)ccc1C(C1=CC=C(*)C[C@]1O1)=C(C=C2)C1=CC2=O)=N)=O 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 1
- 102000013138 Drug Receptors Human genes 0.000 description 1
- 108010065556 Drug Receptors Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- SATIABMUOHRMKS-UHFFFAOYSA-N OC(=O)C1=CC=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 Chemical compound OC(=O)C1=CC=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 SATIABMUOHRMKS-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920001744 Polyaldehyde Polymers 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003922 charged colloid Substances 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000011246 composite particle Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- RWRSPZSWYOMDQL-UHFFFAOYSA-N dipropan-2-yl 2-bromo-2-methylpropanedioate Chemical compound CC(C)OC(=O)C(C)(Br)C(=O)OC(C)C RWRSPZSWYOMDQL-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229950010592 dodecafluoropentane Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000011554 ferrofluid Substances 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- RYHQMKVRYNEBNJ-BMWGJIJESA-K gadoterate meglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 RYHQMKVRYNEBNJ-BMWGJIJESA-K 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- RJMMFJHMVBOLGY-UHFFFAOYSA-N indium(3+) Chemical compound [In+3] RJMMFJHMVBOLGY-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- 239000000797 iron chelating agent Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000001307 laser spectroscopy Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000011271 lymphoscintigraphy Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007896 magnetic source imaging Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000011146 organic particle Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- AJCDFVKYMIUXCR-UHFFFAOYSA-N oxobarium;oxo(oxoferriooxy)iron Chemical compound [Ba]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O.O=[Fe]O[Fe]=O AJCDFVKYMIUXCR-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000005295 random walk Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- VIFBVOSDYUIKIK-UHFFFAOYSA-J sodium;gadolinium(3+);2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate Chemical compound [Na+].[Gd+3].[O-]C(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 VIFBVOSDYUIKIK-UHFFFAOYSA-J 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- JEHASHUIFUSSAI-UHFFFAOYSA-N sulfanylidenetechnetium Chemical compound [Tc]=S JEHASHUIFUSSAI-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- IOWOAQVVLHHFTL-UHFFFAOYSA-N technetium(vii) oxide Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Tc+7].[Tc+7] IOWOAQVVLHHFTL-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229960003853 ultrasound contrast media Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
- A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
- A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU72216/98A AU7221698A (en) | 1997-04-29 | 1998-04-29 | Light imaging contrast agents |
EP98919339A EP0979107A1 (en) | 1997-04-29 | 1998-04-29 | Light imaging contrast agents |
JP54675198A JP2001526650A (en) | 1997-04-29 | 1998-04-29 | Optical contrast agent |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84858697A | 1997-04-29 | 1997-04-29 | |
US08/848,586 | 1997-04-29 | ||
US08/984,771 US6159445A (en) | 1994-07-20 | 1997-12-04 | Light imaging contrast agents |
US08/984,771 | 1997-12-04 | ||
GB9727124.1 | 1997-12-22 | ||
GBGB9727124.1A GB9727124D0 (en) | 1997-12-22 | 1997-12-22 | Compounds |
US3528598A | 1998-03-05 | 1998-03-05 | |
US09/035,285 | 1998-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998048846A1 true WO1998048846A1 (en) | 1998-11-05 |
Family
ID=27451736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/001248 WO1998048846A1 (en) | 1997-04-29 | 1998-04-29 | Light imaging contrast agents |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0979107A1 (en) |
JP (1) | JP2001526650A (en) |
AU (1) | AU7221698A (en) |
WO (1) | WO1998048846A1 (en) |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6217848B1 (en) | 1999-05-20 | 2001-04-17 | Mallinckrodt Inc. | Cyanine and indocyanine dye bioconjugates for biomedical applications |
WO2002038190A2 (en) | 2000-10-27 | 2002-05-16 | Beth Israel Deaconess Medical Center | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates |
US6706254B2 (en) * | 2000-01-18 | 2004-03-16 | Mallinckrodt, Inc. | Receptor-avid exogenous optical contrast and therapeutic agents |
US6748259B1 (en) | 2000-06-15 | 2004-06-08 | Spectros Corporation | Optical imaging of induced signals in vivo under ambient light conditions |
US6761878B2 (en) | 2001-10-17 | 2004-07-13 | Mallinckrodt, Inc. | Pathological tissue detection and treatment employing targeted benzoindole optical agents |
EP1745739A2 (en) | 2005-07-14 | 2007-01-24 | Schering Aktiengesellschaft | Optical imaging of rheumatoid arthritis |
WO2008116010A1 (en) * | 2007-03-19 | 2008-09-25 | The General Hospital Corporation | System and method for providing noninvasive diagnosis of compartment syndrome exemplary laser speckle imaging procedure |
WO2010042476A2 (en) * | 2008-10-09 | 2010-04-15 | President And Fellows Of Harvard College | Methods for making particles having long spin-lattice relaxation times |
EP2201897A2 (en) | 2001-10-17 | 2010-06-30 | Mallinckrodt Inc. | Tumor targeted photodiagnostic-phototherapeutic agents |
US7767194B2 (en) | 2000-01-18 | 2010-08-03 | Mallinckrodt Inc. | Optical diagnostic and therapeutic agents and compositions |
US7850946B2 (en) | 2003-05-31 | 2010-12-14 | Washington University In St. Louis | Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications |
EP2281580A2 (en) | 2003-01-13 | 2011-02-09 | Bracco Imaging S.p.A | Labeled gastrin releasing peptides (GRP) |
US7995210B2 (en) | 2004-11-24 | 2011-08-09 | The General Hospital Corporation | Devices and arrangements for performing coherence range imaging using a common path interferometer |
US7993927B2 (en) | 2006-07-03 | 2011-08-09 | Beth Israel Deaconess Medical Center, Inc. | Histology methods |
JP2012229252A (en) * | 2000-02-08 | 2012-11-22 | Rice Univ | Optically-active nanoparticle for use in therapeutic and diagnostic methods |
USRE43875E1 (en) | 2004-09-29 | 2012-12-25 | The General Hospital Corporation | System and method for optical coherence imaging |
USRE44042E1 (en) | 2004-09-10 | 2013-03-05 | The General Hospital Corporation | System and method for optical coherence imaging |
US8838213B2 (en) | 2006-10-19 | 2014-09-16 | The General Hospital Corporation | Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample, and effecting such portion(s) |
US8861910B2 (en) | 2008-06-20 | 2014-10-14 | The General Hospital Corporation | Fused fiber optic coupler arrangement and method for use thereof |
US8896838B2 (en) | 2010-03-05 | 2014-11-25 | The General Hospital Corporation | Systems, methods and computer-accessible medium which provide microscopic images of at least one anatomical structure at a particular resolution |
US8922781B2 (en) | 2004-11-29 | 2014-12-30 | The General Hospital Corporation | Arrangements, devices, endoscopes, catheters and methods for performing optical imaging by simultaneously illuminating and detecting multiple points on a sample |
US8928889B2 (en) | 2005-09-29 | 2015-01-06 | The General Hospital Corporation | Arrangements and methods for providing multimodality microscopic imaging of one or more biological structures |
US8937724B2 (en) | 2008-12-10 | 2015-01-20 | The General Hospital Corporation | Systems and methods for extending imaging depth range of optical coherence tomography through optical sub-sampling |
US8965487B2 (en) | 2004-08-24 | 2015-02-24 | The General Hospital Corporation | Process, system and software arrangement for measuring a mechanical strain and elastic properties of a sample |
US9060689B2 (en) | 2005-06-01 | 2015-06-23 | The General Hospital Corporation | Apparatus, method and system for performing phase-resolved optical frequency domain imaging |
US9069130B2 (en) | 2010-05-03 | 2015-06-30 | The General Hospital Corporation | Apparatus, method and system for generating optical radiation from biological gain media |
US9087368B2 (en) | 2006-01-19 | 2015-07-21 | The General Hospital Corporation | Methods and systems for optical imaging or epithelial luminal organs by beam scanning thereof |
US9176319B2 (en) | 2007-03-23 | 2015-11-03 | The General Hospital Corporation | Methods, arrangements and apparatus for utilizing a wavelength-swept laser using angular scanning and dispersion procedures |
US9186066B2 (en) | 2006-02-01 | 2015-11-17 | The General Hospital Corporation | Apparatus for applying a plurality of electro-magnetic radiations to a sample |
US9226660B2 (en) | 2004-08-06 | 2016-01-05 | The General Hospital Corporation | Process, system and software arrangement for determining at least one location in a sample using an optical coherence tomography |
US9226665B2 (en) | 2003-01-24 | 2016-01-05 | The General Hospital Corporation | Speckle reduction in optical coherence tomography by path length encoded angular compounding |
US9254102B2 (en) | 2004-08-24 | 2016-02-09 | The General Hospital Corporation | Method and apparatus for imaging of vessel segments |
US9254089B2 (en) | 2008-07-14 | 2016-02-09 | The General Hospital Corporation | Apparatus and methods for facilitating at least partial overlap of dispersed ration on at least one sample |
US9282931B2 (en) | 2000-10-30 | 2016-03-15 | The General Hospital Corporation | Methods for tissue analysis |
US9295391B1 (en) | 2000-11-10 | 2016-03-29 | The General Hospital Corporation | Spectrally encoded miniature endoscopic imaging probe |
US9330092B2 (en) | 2011-07-19 | 2016-05-03 | The General Hospital Corporation | Systems, methods, apparatus and computer-accessible-medium for providing polarization-mode dispersion compensation in optical coherence tomography |
US9326682B2 (en) | 2005-04-28 | 2016-05-03 | The General Hospital Corporation | Systems, processes and software arrangements for evaluating information associated with an anatomical structure by an optical coherence ranging technique |
US9341783B2 (en) | 2011-10-18 | 2016-05-17 | The General Hospital Corporation | Apparatus and methods for producing and/or providing recirculating optical delay(s) |
US9351642B2 (en) | 2009-03-12 | 2016-05-31 | The General Hospital Corporation | Non-contact optical system, computer-accessible medium and method for measurement at least one mechanical property of tissue using coherent speckle technique(s) |
US9364143B2 (en) | 2006-05-10 | 2016-06-14 | The General Hospital Corporation | Process, arrangements and systems for providing frequency domain imaging of a sample |
US9375158B2 (en) | 2007-07-31 | 2016-06-28 | The General Hospital Corporation | Systems and methods for providing beam scan patterns for high speed doppler optical frequency domain imaging |
US9377290B2 (en) | 2003-10-27 | 2016-06-28 | The General Hospital Corporation | Method and apparatus for performing optical imaging using frequency-domain interferometry |
US9441948B2 (en) | 2005-08-09 | 2016-09-13 | The General Hospital Corporation | Apparatus, methods and storage medium for performing polarization-based quadrature demodulation in optical coherence tomography |
US9510758B2 (en) | 2010-10-27 | 2016-12-06 | The General Hospital Corporation | Apparatus, systems and methods for measuring blood pressure within at least one vessel |
US9516997B2 (en) | 2006-01-19 | 2016-12-13 | The General Hospital Corporation | Spectrally-encoded endoscopy techniques, apparatus and methods |
US9557154B2 (en) | 2010-05-25 | 2017-01-31 | The General Hospital Corporation | Systems, devices, methods, apparatus and computer-accessible media for providing optical imaging of structures and compositions |
US9615748B2 (en) | 2009-01-20 | 2017-04-11 | The General Hospital Corporation | Endoscopic biopsy apparatus, system and method |
US9629528B2 (en) | 2012-03-30 | 2017-04-25 | The General Hospital Corporation | Imaging system, method and distal attachment for multidirectional field of view endoscopy |
USRE46412E1 (en) | 2006-02-24 | 2017-05-23 | The General Hospital Corporation | Methods and systems for performing angle-resolved Fourier-domain optical coherence tomography |
US9664615B2 (en) | 2004-07-02 | 2017-05-30 | The General Hospital Corporation | Imaging system and related techniques |
US9668652B2 (en) | 2013-07-26 | 2017-06-06 | The General Hospital Corporation | System, apparatus and method for utilizing optical dispersion for fourier-domain optical coherence tomography |
US9733460B2 (en) | 2014-01-08 | 2017-08-15 | The General Hospital Corporation | Method and apparatus for microscopic imaging |
US9777053B2 (en) | 2006-02-08 | 2017-10-03 | The General Hospital Corporation | Methods, arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy |
US9784681B2 (en) | 2013-05-13 | 2017-10-10 | The General Hospital Corporation | System and method for efficient detection of the phase and amplitude of a periodic modulation associated with self-interfering fluorescence |
US9795301B2 (en) | 2010-05-25 | 2017-10-24 | The General Hospital Corporation | Apparatus, systems, methods and computer-accessible medium for spectral analysis of optical coherence tomography images |
US9968261B2 (en) | 2013-01-28 | 2018-05-15 | The General Hospital Corporation | Apparatus and method for providing diffuse spectroscopy co-registered with optical frequency domain imaging |
US10117576B2 (en) | 2013-07-19 | 2018-11-06 | The General Hospital Corporation | System, method and computer accessible medium for determining eye motion by imaging retina and providing feedback for acquisition of signals from the retina |
US10228556B2 (en) | 2014-04-04 | 2019-03-12 | The General Hospital Corporation | Apparatus and method for controlling propagation and/or transmission of electromagnetic radiation in flexible waveguide(s) |
US10241028B2 (en) | 2011-08-25 | 2019-03-26 | The General Hospital Corporation | Methods, systems, arrangements and computer-accessible medium for providing micro-optical coherence tomography procedures |
US10285568B2 (en) | 2010-06-03 | 2019-05-14 | The General Hospital Corporation | Apparatus and method for devices for imaging structures in or at one or more luminal organs |
US10426548B2 (en) | 2006-02-01 | 2019-10-01 | The General Hosppital Corporation | Methods and systems for providing electromagnetic radiation to at least one portion of a sample using conformal laser therapy procedures |
USRE47675E1 (en) | 2003-06-06 | 2019-10-29 | The General Hospital Corporation | Process and apparatus for a wavelength tuning source |
US10478072B2 (en) | 2013-03-15 | 2019-11-19 | The General Hospital Corporation | Methods and system for characterizing an object |
US10534129B2 (en) | 2007-03-30 | 2020-01-14 | The General Hospital Corporation | System and method providing intracoronary laser speckle imaging for the detection of vulnerable plaque |
US10736494B2 (en) | 2014-01-31 | 2020-08-11 | The General Hospital Corporation | System and method for facilitating manual and/or automatic volumetric imaging with real-time tension or force feedback using a tethered imaging device |
US10806804B2 (en) | 2015-05-06 | 2020-10-20 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
US10893806B2 (en) | 2013-01-29 | 2021-01-19 | The General Hospital Corporation | Apparatus, systems and methods for providing information regarding the aortic valve |
US10904518B2 (en) | 2012-01-23 | 2021-01-26 | Washington University | Goggle imaging systems and methods |
US10912462B2 (en) | 2014-07-25 | 2021-02-09 | The General Hospital Corporation | Apparatus, devices and methods for in vivo imaging and diagnosis |
US11179028B2 (en) | 2013-02-01 | 2021-11-23 | The General Hospital Corporation | Objective lens arrangement for confocal endomicroscopy |
US11406719B2 (en) | 2008-02-18 | 2022-08-09 | Washington University | Dichromic fluorescent compounds |
US11452433B2 (en) | 2013-07-19 | 2022-09-27 | The General Hospital Corporation | Imaging apparatus and method which utilizes multidirectional field of view endoscopy |
US11490797B2 (en) | 2012-05-21 | 2022-11-08 | The General Hospital Corporation | Apparatus, device and method for capsule microscopy |
US11490826B2 (en) | 2009-07-14 | 2022-11-08 | The General Hospital Corporation | Apparatus, systems and methods for measuring flow and pressure within a vessel |
US11712482B2 (en) | 2019-12-13 | 2023-08-01 | Washington University | Near infrared fluorescent dyes, formulations and related methods |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4597744B2 (en) | 2004-11-08 | 2010-12-15 | 株式会社トプコン | Optical image measuring device and optical image measuring method |
ES2627998T3 (en) * | 2005-11-16 | 2017-08-01 | Exchange Imaging Technologies Gmbh | Fluorescent nanoparticles |
JP2007223966A (en) * | 2006-02-24 | 2007-09-06 | Pentax Corp | Cell surface- or tissue surface-staining agent composition and staining method using the same |
WO2008102065A1 (en) * | 2007-02-14 | 2008-08-28 | Commissariat A L'energie Atomique | Fluorescent emulsions for optical imaging |
FR2934953B1 (en) | 2008-08-14 | 2011-01-21 | Commissariat Energie Atomique | NANO-CRYSTALS NANOEMULSIONS |
FR2934954B1 (en) | 2008-08-14 | 2011-07-22 | Commissariat Energie Atomique | FLUORESCENT EMULSION OF INDOCYANINE GREEN |
FR2934955B1 (en) | 2008-08-14 | 2011-07-08 | Commissariat Energie Atomique | ENCAPSULATION OF LIPOPHILIC OR AMPHIPHILIC THERAPEUTIC AGENTS IN NANOEMULSIONS |
US9814417B2 (en) * | 2009-01-13 | 2017-11-14 | Longevity Link Corporation | Noninvasive measurement of flavonoid compounds in biological tissue |
WO2012026608A1 (en) * | 2010-08-24 | 2012-03-01 | Canon Kabushiki Kaisha | Polymeric particle and hydrophilic dye having a sulfonate group encapsulated within the particle |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023524A1 (en) * | 1995-02-02 | 1996-08-08 | Nycomed Imaging A/S | Contrast media for in vivo imaging based on light transmission on reflection |
WO1996034853A1 (en) * | 1995-05-01 | 1996-11-07 | University Of Pittsburgh | Azocompounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
WO1997018841A1 (en) * | 1994-07-01 | 1997-05-29 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
-
1998
- 1998-04-29 AU AU72216/98A patent/AU7221698A/en not_active Abandoned
- 1998-04-29 EP EP98919339A patent/EP0979107A1/en not_active Withdrawn
- 1998-04-29 WO PCT/GB1998/001248 patent/WO1998048846A1/en not_active Application Discontinuation
- 1998-04-29 JP JP54675198A patent/JP2001526650A/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997018841A1 (en) * | 1994-07-01 | 1997-05-29 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
WO1996023524A1 (en) * | 1995-02-02 | 1996-08-08 | Nycomed Imaging A/S | Contrast media for in vivo imaging based on light transmission on reflection |
WO1996034853A1 (en) * | 1995-05-01 | 1996-11-07 | University Of Pittsburgh | Azocompounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
Non-Patent Citations (22)
Title |
---|
AM. J. PHYSIOL. (1995), 269(1, PT. 1), L11-L19 CODEN: AJPHAP;ISSN: 0002-9513, 1995, XP002074149 * |
CHEMICAL ABSTRACTS, vol. 104, no. 7, 17 February 1986, Columbus, Ohio, US; abstract no. 47950, TSUDA, YOSHIO ET AL: "Perfluorooctyl bromide emulsion contrast agent for tumors" XP002074154 * |
CHEMICAL ABSTRACTS, vol. 123, Columbus, Ohio, US; abstract no. 160008, MULLER, W. J. ET AL: "Pathways for uptake of fluorescently labeled liposomes by alveolar type II cells in culture" XP002074158 * |
CHEMICAL ABSTRACTS, vol. 125, Columbus, Ohio, US; abstract no. 184820, CARR, KATHARINE E. ET AL: "The effect of size on uptake of orally administered latex microparticles in the small intestine and transport to mesenteric lymph nodes" XP002074157 * |
CHEMICAL ABSTRACTS, vol. 128, Columbus, Ohio, US; abstract no. 208843, MIZUSHIMA, YUTAKA ET AL: "Targeting delivery of prostanoids and bioactive proteins" XP002074156 * |
CHEMICAL ABSTRACTS, vol. 129, Columbus, Ohio, US; abstract no. 14010, HASEGAWA, MASAKATSU ET AL: "Biological behavior of dextran-iron oxide magnetic fluid injected intravenously in rats" XP002074155 * |
CHEMICAL ABSTRACTS, vol. 129, Columbus, Ohio, US; abstract no. 8501, THURSTON, GAVIN ET AL: "Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice" XP002074159 * |
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; XP002074160 * |
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; XP002074161 * |
DENK W ET AL: "TWO-PHOTON LASER SCANNING FLUORESCENCE MICROSCOPY", SCIENCE, vol. 248, no. 4951, 6 April 1990 (1990-04-06), pages 73 - 76, XP000381741 * |
J. CLIN. INVEST. (1998), 101(7), 1401-1413 CODEN: JCINAO;ISSN: 0021-9738, 1998, XP002074153 * |
JPN. J. APPL. PHYS., PART 1 (1998), 37(3A), 1029-1032 CODEN: JAPNDE;ISSN: 0021-4922, 1998, XP002074143 * |
LAMY-FREUND, M. THERESA ET AL: "Characterization and time dependence of amphotericin B: deoxycholate aggregation by quasielastic light scattering", J. PHARM. SCI. (1991), 80(3), 262-6 CODEN: JPMSAE;ISSN: 0022-3549, 1991, pages 262 - 266, XP002074146 * |
M. RAJADHYAKSHA ET AL.: "In vivo confocal scanning laser microscopy of human skin: melanin provides strong contrast.", J. INVESTIG. DERMAT., vol. 104, no. 6, June 1995 (1995-06-01), pages 946 - 952, XP002074150 * |
MED. CHEM.: TODAY TOMORROW, PROC. AFMC INT. MED. CHEM. SYMP. (1997), MEETING DATE 1995, 23-28. EDITOR(S): YAMAZAKI, MIKIO. PUBLISHER: BLACKWELL, OXFORD, UK. CODEN: 65ONAG, 1997, XP002074147 * |
NIPPON KAGAKU KAISHI (1985), (10), 1846-50 CODEN: NKAKB8;ISSN: 0369-4577, 1985, XP002074142 * |
PHARM. RES. (1996), 13(8), 1205-1209 CODEN: PHREEB;ISSN: 0724-8741, 1996, XP002074148 * |
SABEL B.A. ET AL.: "In vivo confocal neuroimaging (ICON) of CNS neurons.", NATURE MEDICINE., vol. 3, no. 2, February 1997 (1997-02-01), CO US, pages 244 - 247, XP002074151 * |
STAVRAKY R.T. ET AL.: "Baseline consideration of liposomal contrast agent CNS transport by macrophages in experimental allergic encephalomyelitis.", MAGN. RESON. IMAGING, vol. 11, no. 5, 1993, pages 685 - 689, XP002074145 * |
W. DENK ET AL.: "Anatomical and functional imaging of neurons using 2-photon laser scanning microscopy.", J. NEUROSCIENCE METHODS, vol. 54, no. 2, October 1994 (1994-10-01), pages 151 - 162, XP002074152 * |
YAN C ET AL: "Characterization and morphological analysis of protein-loaded poly(lactide-co-glycolide) microparticles prepared by water-in-oil -in-water emulsion technique", JOURNAL OF CONTROLLED RELEASE, vol. 32, no. 3, 1 December 1994 (1994-12-01), pages 231-241, XP004037656 * |
ZHOU X. ET AL.: "THREE-D NMR MICROSCOPY OF RAT SPLEEN AND LIVER.", MAGNETIC RESONANCE IN MEDICINE., vol. 30, no. 1, July 1993 (1993-07-01), MN US, pages 92 - 97, XP002074144 * |
Cited By (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2058007A2 (en) | 1999-05-20 | 2009-05-13 | Mallinckrodt, Inc. | Cyanine and indocyanine dye bioconjugates for biomedical applications |
US6217848B1 (en) | 1999-05-20 | 2001-04-17 | Mallinckrodt Inc. | Cyanine and indocyanine dye bioconjugates for biomedical applications |
US7767194B2 (en) | 2000-01-18 | 2010-08-03 | Mallinckrodt Inc. | Optical diagnostic and therapeutic agents and compositions |
US7790144B2 (en) | 2000-01-18 | 2010-09-07 | Mallinckrodt Inc. | Receptor-avid exogenous optical contrast and therapeutic agents |
US6706254B2 (en) * | 2000-01-18 | 2004-03-16 | Mallinckrodt, Inc. | Receptor-avid exogenous optical contrast and therapeutic agents |
JP2012229252A (en) * | 2000-02-08 | 2012-11-22 | Rice Univ | Optically-active nanoparticle for use in therapeutic and diagnostic methods |
US6748259B1 (en) | 2000-06-15 | 2004-06-08 | Spectros Corporation | Optical imaging of induced signals in vivo under ambient light conditions |
US7668587B2 (en) | 2000-06-15 | 2010-02-23 | Spectros Corporation | Optical imaging of induced signals in vivo under ambient light conditions |
US6869593B2 (en) | 2000-10-27 | 2005-03-22 | Beth Israel Deaconess Medical Center | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates |
WO2002038190A2 (en) | 2000-10-27 | 2002-05-16 | Beth Israel Deaconess Medical Center | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates |
US7374746B2 (en) | 2000-10-27 | 2008-05-20 | Beth Israel Deaconees Medical Center | Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates |
US9282931B2 (en) | 2000-10-30 | 2016-03-15 | The General Hospital Corporation | Methods for tissue analysis |
US9295391B1 (en) | 2000-11-10 | 2016-03-29 | The General Hospital Corporation | Spectrally encoded miniature endoscopic imaging probe |
US7201892B2 (en) | 2001-10-17 | 2007-04-10 | Mallinckrodt Inc. | Pathological tissue detection and treatment employing targeted optical agents |
US7510700B2 (en) | 2001-10-17 | 2009-03-31 | Mallinckrodt Inc | Pathological tissue detection and treatment employing targeted benzoindole optical agents |
US7252815B2 (en) | 2001-10-17 | 2007-08-07 | Mallinckrodt, Inc. | Pathological tissue detection and treatment employing targeted benzoindole optical agents |
EP2201897A2 (en) | 2001-10-17 | 2010-06-30 | Mallinckrodt Inc. | Tumor targeted photodiagnostic-phototherapeutic agents |
US7128896B2 (en) | 2001-10-17 | 2006-10-31 | Mallinckrodt Inc. | Pathological tissue detection and treatment employing targeted benzoindole optical agents |
US6761878B2 (en) | 2001-10-17 | 2004-07-13 | Mallinckrodt, Inc. | Pathological tissue detection and treatment employing targeted benzoindole optical agents |
EP2281580A2 (en) | 2003-01-13 | 2011-02-09 | Bracco Imaging S.p.A | Labeled gastrin releasing peptides (GRP) |
EP2500040A1 (en) | 2003-01-13 | 2012-09-19 | Bracco Imaging S.p.A | Improved Gastrin Releasing Peptide Receptor-Binding Compounds |
US9226665B2 (en) | 2003-01-24 | 2016-01-05 | The General Hospital Corporation | Speckle reduction in optical coherence tomography by path length encoded angular compounding |
US8318133B2 (en) | 2003-05-31 | 2012-11-27 | Washington University In St. Louis | Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications |
US7850946B2 (en) | 2003-05-31 | 2010-12-14 | Washington University In St. Louis | Macrocyclic cyanine and indocyanine bioconjugates provide improved biomedical applications |
USRE47675E1 (en) | 2003-06-06 | 2019-10-29 | The General Hospital Corporation | Process and apparatus for a wavelength tuning source |
US9812846B2 (en) | 2003-10-27 | 2017-11-07 | The General Hospital Corporation | Method and apparatus for performing optical imaging using frequency-domain interferometry |
US9377290B2 (en) | 2003-10-27 | 2016-06-28 | The General Hospital Corporation | Method and apparatus for performing optical imaging using frequency-domain interferometry |
US9664615B2 (en) | 2004-07-02 | 2017-05-30 | The General Hospital Corporation | Imaging system and related techniques |
US9226660B2 (en) | 2004-08-06 | 2016-01-05 | The General Hospital Corporation | Process, system and software arrangement for determining at least one location in a sample using an optical coherence tomography |
US9763623B2 (en) | 2004-08-24 | 2017-09-19 | The General Hospital Corporation | Method and apparatus for imaging of vessel segments |
US8965487B2 (en) | 2004-08-24 | 2015-02-24 | The General Hospital Corporation | Process, system and software arrangement for measuring a mechanical strain and elastic properties of a sample |
US9254102B2 (en) | 2004-08-24 | 2016-02-09 | The General Hospital Corporation | Method and apparatus for imaging of vessel segments |
USRE44042E1 (en) | 2004-09-10 | 2013-03-05 | The General Hospital Corporation | System and method for optical coherence imaging |
USRE43875E1 (en) | 2004-09-29 | 2012-12-25 | The General Hospital Corporation | System and method for optical coherence imaging |
USRE45512E1 (en) | 2004-09-29 | 2015-05-12 | The General Hospital Corporation | System and method for optical coherence imaging |
US7995210B2 (en) | 2004-11-24 | 2011-08-09 | The General Hospital Corporation | Devices and arrangements for performing coherence range imaging using a common path interferometer |
US8922781B2 (en) | 2004-11-29 | 2014-12-30 | The General Hospital Corporation | Arrangements, devices, endoscopes, catheters and methods for performing optical imaging by simultaneously illuminating and detecting multiple points on a sample |
US9326682B2 (en) | 2005-04-28 | 2016-05-03 | The General Hospital Corporation | Systems, processes and software arrangements for evaluating information associated with an anatomical structure by an optical coherence ranging technique |
US9060689B2 (en) | 2005-06-01 | 2015-06-23 | The General Hospital Corporation | Apparatus, method and system for performing phase-resolved optical frequency domain imaging |
EP1745739A2 (en) | 2005-07-14 | 2007-01-24 | Schering Aktiengesellschaft | Optical imaging of rheumatoid arthritis |
US9441948B2 (en) | 2005-08-09 | 2016-09-13 | The General Hospital Corporation | Apparatus, methods and storage medium for performing polarization-based quadrature demodulation in optical coherence tomography |
US8928889B2 (en) | 2005-09-29 | 2015-01-06 | The General Hospital Corporation | Arrangements and methods for providing multimodality microscopic imaging of one or more biological structures |
US9304121B2 (en) | 2005-09-29 | 2016-04-05 | The General Hospital Corporation | Method and apparatus for optical imaging via spectral encoding |
US9513276B2 (en) | 2005-09-29 | 2016-12-06 | The General Hospital Corporation | Method and apparatus for optical imaging via spectral encoding |
US10987000B2 (en) | 2006-01-19 | 2021-04-27 | The General Hospital Corporation | Methods and systems for optical imaging or epithelial luminal organs by beam scanning thereof |
US9791317B2 (en) | 2006-01-19 | 2017-10-17 | The General Hospital Corporation | Spectrally-encoded endoscopy techniques and methods |
US9516997B2 (en) | 2006-01-19 | 2016-12-13 | The General Hospital Corporation | Spectrally-encoded endoscopy techniques, apparatus and methods |
US9087368B2 (en) | 2006-01-19 | 2015-07-21 | The General Hospital Corporation | Methods and systems for optical imaging or epithelial luminal organs by beam scanning thereof |
US9646377B2 (en) | 2006-01-19 | 2017-05-09 | The General Hospital Corporation | Methods and systems for optical imaging or epithelial luminal organs by beam scanning thereof |
US9186066B2 (en) | 2006-02-01 | 2015-11-17 | The General Hospital Corporation | Apparatus for applying a plurality of electro-magnetic radiations to a sample |
US9186067B2 (en) | 2006-02-01 | 2015-11-17 | The General Hospital Corporation | Apparatus for applying a plurality of electro-magnetic radiations to a sample |
US10426548B2 (en) | 2006-02-01 | 2019-10-01 | The General Hosppital Corporation | Methods and systems for providing electromagnetic radiation to at least one portion of a sample using conformal laser therapy procedures |
US9777053B2 (en) | 2006-02-08 | 2017-10-03 | The General Hospital Corporation | Methods, arrangements and systems for obtaining information associated with an anatomical sample using optical microscopy |
USRE46412E1 (en) | 2006-02-24 | 2017-05-23 | The General Hospital Corporation | Methods and systems for performing angle-resolved Fourier-domain optical coherence tomography |
US9364143B2 (en) | 2006-05-10 | 2016-06-14 | The General Hospital Corporation | Process, arrangements and systems for providing frequency domain imaging of a sample |
US10413175B2 (en) | 2006-05-10 | 2019-09-17 | The General Hospital Corporation | Process, arrangements and systems for providing frequency domain imaging of a sample |
US7993927B2 (en) | 2006-07-03 | 2011-08-09 | Beth Israel Deaconess Medical Center, Inc. | Histology methods |
US8838213B2 (en) | 2006-10-19 | 2014-09-16 | The General Hospital Corporation | Apparatus and method for obtaining and providing imaging information associated with at least one portion of a sample, and effecting such portion(s) |
WO2008116010A1 (en) * | 2007-03-19 | 2008-09-25 | The General Hospital Corporation | System and method for providing noninvasive diagnosis of compartment syndrome exemplary laser speckle imaging procedure |
US9176319B2 (en) | 2007-03-23 | 2015-11-03 | The General Hospital Corporation | Methods, arrangements and apparatus for utilizing a wavelength-swept laser using angular scanning and dispersion procedures |
US10534129B2 (en) | 2007-03-30 | 2020-01-14 | The General Hospital Corporation | System and method providing intracoronary laser speckle imaging for the detection of vulnerable plaque |
US9375158B2 (en) | 2007-07-31 | 2016-06-28 | The General Hospital Corporation | Systems and methods for providing beam scan patterns for high speed doppler optical frequency domain imaging |
US11406719B2 (en) | 2008-02-18 | 2022-08-09 | Washington University | Dichromic fluorescent compounds |
US8861910B2 (en) | 2008-06-20 | 2014-10-14 | The General Hospital Corporation | Fused fiber optic coupler arrangement and method for use thereof |
US10835110B2 (en) | 2008-07-14 | 2020-11-17 | The General Hospital Corporation | Apparatus and method for facilitating at least partial overlap of dispersed ration on at least one sample |
US9254089B2 (en) | 2008-07-14 | 2016-02-09 | The General Hospital Corporation | Apparatus and methods for facilitating at least partial overlap of dispersed ration on at least one sample |
WO2010042476A2 (en) * | 2008-10-09 | 2010-04-15 | President And Fellows Of Harvard College | Methods for making particles having long spin-lattice relaxation times |
WO2010042476A3 (en) * | 2008-10-09 | 2011-08-25 | President And Fellows Of Harvard College | Methods for making particles having long spin-lattice relaxation times |
US8937724B2 (en) | 2008-12-10 | 2015-01-20 | The General Hospital Corporation | Systems and methods for extending imaging depth range of optical coherence tomography through optical sub-sampling |
US9615748B2 (en) | 2009-01-20 | 2017-04-11 | The General Hospital Corporation | Endoscopic biopsy apparatus, system and method |
US9351642B2 (en) | 2009-03-12 | 2016-05-31 | The General Hospital Corporation | Non-contact optical system, computer-accessible medium and method for measurement at least one mechanical property of tissue using coherent speckle technique(s) |
US11490826B2 (en) | 2009-07-14 | 2022-11-08 | The General Hospital Corporation | Apparatus, systems and methods for measuring flow and pressure within a vessel |
US9081148B2 (en) | 2010-03-05 | 2015-07-14 | The General Hospital Corporation | Systems, methods and computer-accessible medium which provide microscopic images of at least one anatomical structure at a particular resolution |
US9642531B2 (en) | 2010-03-05 | 2017-05-09 | The General Hospital Corporation | Systems, methods and computer-accessible medium which provide microscopic images of at least one anatomical structure at a particular resolution |
US9408539B2 (en) | 2010-03-05 | 2016-08-09 | The General Hospital Corporation | Systems, methods and computer-accessible medium which provide microscopic images of at least one anatomical structure at a particular resolution |
US10463254B2 (en) | 2010-03-05 | 2019-11-05 | The General Hospital Corporation | Light tunnel and lens which provide extended focal depth of at least one anatomical structure at a particular resolution |
US8896838B2 (en) | 2010-03-05 | 2014-11-25 | The General Hospital Corporation | Systems, methods and computer-accessible medium which provide microscopic images of at least one anatomical structure at a particular resolution |
US9069130B2 (en) | 2010-05-03 | 2015-06-30 | The General Hospital Corporation | Apparatus, method and system for generating optical radiation from biological gain media |
US9951269B2 (en) | 2010-05-03 | 2018-04-24 | The General Hospital Corporation | Apparatus, method and system for generating optical radiation from biological gain media |
US9557154B2 (en) | 2010-05-25 | 2017-01-31 | The General Hospital Corporation | Systems, devices, methods, apparatus and computer-accessible media for providing optical imaging of structures and compositions |
US9795301B2 (en) | 2010-05-25 | 2017-10-24 | The General Hospital Corporation | Apparatus, systems, methods and computer-accessible medium for spectral analysis of optical coherence tomography images |
US10939825B2 (en) | 2010-05-25 | 2021-03-09 | The General Hospital Corporation | Systems, devices, methods, apparatus and computer-accessible media for providing optical imaging of structures and compositions |
US10285568B2 (en) | 2010-06-03 | 2019-05-14 | The General Hospital Corporation | Apparatus and method for devices for imaging structures in or at one or more luminal organs |
US9510758B2 (en) | 2010-10-27 | 2016-12-06 | The General Hospital Corporation | Apparatus, systems and methods for measuring blood pressure within at least one vessel |
US9330092B2 (en) | 2011-07-19 | 2016-05-03 | The General Hospital Corporation | Systems, methods, apparatus and computer-accessible-medium for providing polarization-mode dispersion compensation in optical coherence tomography |
US10241028B2 (en) | 2011-08-25 | 2019-03-26 | The General Hospital Corporation | Methods, systems, arrangements and computer-accessible medium for providing micro-optical coherence tomography procedures |
US9341783B2 (en) | 2011-10-18 | 2016-05-17 | The General Hospital Corporation | Apparatus and methods for producing and/or providing recirculating optical delay(s) |
US10904518B2 (en) | 2012-01-23 | 2021-01-26 | Washington University | Goggle imaging systems and methods |
US11310485B2 (en) | 2012-01-23 | 2022-04-19 | Washington University | Goggle imaging systems and methods |
US11765340B2 (en) | 2012-01-23 | 2023-09-19 | Washington University | Goggle imaging systems and methods |
US9629528B2 (en) | 2012-03-30 | 2017-04-25 | The General Hospital Corporation | Imaging system, method and distal attachment for multidirectional field of view endoscopy |
US11490797B2 (en) | 2012-05-21 | 2022-11-08 | The General Hospital Corporation | Apparatus, device and method for capsule microscopy |
US9968261B2 (en) | 2013-01-28 | 2018-05-15 | The General Hospital Corporation | Apparatus and method for providing diffuse spectroscopy co-registered with optical frequency domain imaging |
US10893806B2 (en) | 2013-01-29 | 2021-01-19 | The General Hospital Corporation | Apparatus, systems and methods for providing information regarding the aortic valve |
US11179028B2 (en) | 2013-02-01 | 2021-11-23 | The General Hospital Corporation | Objective lens arrangement for confocal endomicroscopy |
US10478072B2 (en) | 2013-03-15 | 2019-11-19 | The General Hospital Corporation | Methods and system for characterizing an object |
US9784681B2 (en) | 2013-05-13 | 2017-10-10 | The General Hospital Corporation | System and method for efficient detection of the phase and amplitude of a periodic modulation associated with self-interfering fluorescence |
US10117576B2 (en) | 2013-07-19 | 2018-11-06 | The General Hospital Corporation | System, method and computer accessible medium for determining eye motion by imaging retina and providing feedback for acquisition of signals from the retina |
US11452433B2 (en) | 2013-07-19 | 2022-09-27 | The General Hospital Corporation | Imaging apparatus and method which utilizes multidirectional field of view endoscopy |
US10058250B2 (en) | 2013-07-26 | 2018-08-28 | The General Hospital Corporation | System, apparatus and method for utilizing optical dispersion for fourier-domain optical coherence tomography |
US9668652B2 (en) | 2013-07-26 | 2017-06-06 | The General Hospital Corporation | System, apparatus and method for utilizing optical dispersion for fourier-domain optical coherence tomography |
US9733460B2 (en) | 2014-01-08 | 2017-08-15 | The General Hospital Corporation | Method and apparatus for microscopic imaging |
US10736494B2 (en) | 2014-01-31 | 2020-08-11 | The General Hospital Corporation | System and method for facilitating manual and/or automatic volumetric imaging with real-time tension or force feedback using a tethered imaging device |
US10228556B2 (en) | 2014-04-04 | 2019-03-12 | The General Hospital Corporation | Apparatus and method for controlling propagation and/or transmission of electromagnetic radiation in flexible waveguide(s) |
US10912462B2 (en) | 2014-07-25 | 2021-02-09 | The General Hospital Corporation | Apparatus, devices and methods for in vivo imaging and diagnosis |
US10806804B2 (en) | 2015-05-06 | 2020-10-20 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
US11413359B2 (en) | 2015-05-06 | 2022-08-16 | Washington University | Compounds having RD targeting motifs and methods of use thereof |
US11712482B2 (en) | 2019-12-13 | 2023-08-01 | Washington University | Near infrared fluorescent dyes, formulations and related methods |
Also Published As
Publication number | Publication date |
---|---|
AU7221698A (en) | 1998-11-24 |
JP2001526650A (en) | 2001-12-18 |
EP0979107A1 (en) | 2000-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6159445A (en) | Light imaging contrast agents | |
US6540981B2 (en) | Light imaging contrast agents | |
EP0808175B1 (en) | Contrast media for in vivo imaging based on light transmission or reflection | |
WO1998048846A1 (en) | Light imaging contrast agents | |
Porcu et al. | Indocyanine green delivery systems for tumour detection and treatments | |
EP0991429B1 (en) | Use of acousto-optical and sonoluminescence contrast agents in diagnostic methods | |
Xu et al. | Nanoliposomes co-encapsulating CT imaging contrast agent and photosensitizer for enhanced, imaging guided photodynamic therapy of cancer | |
JP5837279B2 (en) | Fluorescent emulsion for optical imaging | |
US10264974B2 (en) | High resolution imaging using near-infrared-II fluorescence | |
Ghoroghchian et al. | In vivo fluorescence imaging: a personal perspective | |
US6662040B1 (en) | Methods of photoacoustic imaging | |
JP5559790B2 (en) | Indocyanine green fluorescent emulsion | |
KR19990044581A (en) | Near-infrared diagnostic contrast agent containing colloids containing polymethine dyes | |
US11446391B2 (en) | Amphiphilic dye-coated inorganic nanoparticle clusters | |
Liu et al. | Recent advances in ultrasound-controlled fluorescence technology for deep tissue optical imaging | |
WO1999013916A2 (en) | Methods and compositions for medical imaging | |
Hollis et al. | Hybrid nanocrystal as a versatile platform for cancer theranostics | |
Li et al. | Photoacoustic tomography enhanced by nanoparticles | |
MXPA97005829A (en) | Contrast medium for formation of in vivo images based on transmission or reflection of | |
CN1179108A (en) | Contrast media for in vivo imaging based on light transmission on reflection | |
Pansare | Fundamental and applied studies in nanoparticle biomedical imaging, stabilization, and processing | |
Alves | Desenvolvimento de nanomateriais contendo IR780 para aplicação na terapia do cancro | |
Sadoqi et al. | Tumor Diagnosis and Therapy | |
Gravier et al. | FRET as a Tool for the Investigation of the Fate of Lipidots Contrast Agents in Vivo | |
Saxena | Development of a polymeric nanoparticulate delivery system for indocyanine green |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09429346 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 546751 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998919339 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998919339 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998919339 Country of ref document: EP |